ADMA Biologics Reports Strong Q3 2025 Financial Results

ADMA Biologics Inc ( (ADMA) ) has released its Q3 earnings. Here is a breakdown of the information ADMA Biologics Inc presented to its investors.

ADMA Biologics, Inc. is a U.S.-based biopharmaceutical company specializing in the manufacturing, marketing, and development of specialty biologics, particularly plasma-derived products for immunodeficient patients. The company has announced its third-quarter 2025 financial results, highlighting a 12% year-over-year increase in total revenue to $134.2 million and a 1% increase in GAAP net income to $36.4 million. Adjusted EBITDA saw a significant rise of 29% to $58.7 million, reflecting strong operational performance.

Key financial metrics indicate robust growth, with ADMA Biologics raising its full-year 2025 revenue guidance to at least $510 million and projecting 2026 revenue to exceed $630 million. The company is also advancing its SG-001 pipeline program and has submitted a CNPV voucher application, which could accelerate FDA review. The FDA’s lot release of yield-enhanced production batches is expected to drive margin expansion starting in the fourth quarter of 2025.

ADMA Biologics has achieved record demand for its ASCENIV product, with positive real-world health outcomes demonstrating a significant reduction in infection rates. The company is engaged in discussions to expand its distribution network and anticipates payer coverage expansion in 2026, supporting sustained revenue growth. Additionally, ADMA continues to strengthen its capital structure through share repurchases and disciplined capital deployment.

Looking ahead, ADMA Biologics is optimistic about its growth trajectory, with expectations of exceeding $1.1 billion in annual revenue by 2029. The company is well-positioned to capitalize on operational efficiencies, expanding margins, and a strong pipeline, aiming to deliver long-term value to its stockholders.